Pharmacogenetics of hypertension: randomized monocentric study in patients with essential hypertension and treated with Spironolactone or Torasemide - Pharmacogenetics of hypertension: study with Spironolactone or Torasemide

OSPEDALE SAN RAFFAELE0 个研究点目标入组 144 人开始时间: 2020年10月21日最近更新: 2021年1月11日

试验速览

暂无简介。

•a. male patients aged 25-65 years and female patients aged 45-65 years in menopause
•b. naïve hypertensive patients (newly diagnosed, never previously treated) or in therapy with a single anti-hypertensive drug
•c. documented hypertension of grade I or II (according to ESH 2013 guidelines, in the untreated patient or despite the therapy).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 144
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•a. known causes of secondary hypertension
•b. stage II hypertension (SBP = 180 and DBP = 110 mmHg;
•c. history of renal artery stenosis
•d. significant kidney disease (eGFR-CK-EPI less than 60 ml/min)
•e. refractory hypokalaemia or hyponatraemia (plasma Na < 126 mEq/L)
•f. hyperkalaemia (plasma K > 5.5 mEq/L)
•g. hypercalcaemia
•h. symptomatic hyperuricemia
•i. liver disease (transaminases greater than 3 times the maximum laboratory value)
•j. cardiac pathologies (previous myocardial infarction, ongoing atrial fibrillation, etc.)
•k. diabetes (fasting blood sugar > 126mg/dL)
•l. treatment with statins in progress
•m. obesity (BMI > 30 kg/m2)
•n. known hypersensitivity to the study drugs (Spironolactone or Torasemide) or to any of the excipients

发起方

OSPEDALE SAN RAFFAELE